+91 80 2808 2808
Biocon  /  Patient Stories  /  Bevacizumab

Bevacizumab shows the way for affordable, accessible cancer care!

Neelam's fight against ascites and ovarian cancer

Neelam was a loving home maker who loved living every moment to its fullest. But unfortunately, life had other plans for her. In February 2019, following repeated complaints of diarrhea and bloating, she was advised a CT and PET scan by her gastroenterologist. The news was so very disheartening. Neelam was diagnosed with ascites (abnormal build-up of fluid in the abdomen) and ovarian cancer.

She was immediately referred to a medical oncologist who advised her to undergo 3 cycles of chemotherapy comprising Carboplatin and Paclitaxel. Neelam had to undergo surgery after this, followed by 5 cycles of chemotherapy again – this time with Bevacizumab.


Bevacizumab is a humanised monoclonal antibody that prevents the process of angiogenesis (new vessels formation) and helps patients with ovarian cancer by preventing further cancerous growth. In 2018, the NCCN guideline approved of the use of Bevacizumab in combination with Carboplatin and Paclitaxel, followed by Bevacizumab alone, for patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.


This world-class biosimilar has brought immense relief for patients like Neelam, who need both affordable and accessible cancer care. Today, it is widely accepted as a standard treatment option in combination with chemotherapy. Since biologic products require stringent storage conditions to maintain purity and potency, Biocon developed the world’s first and only Bevacizumab product with a unique ‘Qual-Check’ mechanism that ensures patients get a quality-ascertained product right up to infusion.


Currently, Neelam is not only fighting cancer bravely but also living a normal life, while bringing hope to many patients like her. “A positive mindset can help win over cancer, so never give up on that” she says smiling. For millions like Neelam, this is the beginning of a new chapter in life, for us, this is the beginning of a new chapter in affordable healthcare.

Read more

Pooja Hurkat’s struggle with TYPE 1 diabetes
Kumudha Raju fighting HER2-Positive breast cancer
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>